← Back to Search

Other

Disulfiram for Multiple Myeloma (Repurpose-1 Trial)

Phase 1
Waitlist Available
Led By Douglas Sborov, MD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time from cycle one day one until cycle two day one (28 days)
Awards & highlights

Repurpose-1 Trial Summary

This trial is testing a new combination of drugs to treat patients with multiple myeloma who have not responded to other treatments. The goal is to find the best dose of the combination, assess its safety and tolerability, and expand the cohort to further characterize the combination.

Eligible Conditions
  • Multiple Myeloma

Repurpose-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time from cycle one day one until cycle two day one (28 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and time from cycle one day one until cycle two day one (28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of dose limiting toxicities (DLTs) during the DLT evaluation period.

Repurpose-1 Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment: all patientsExperimental Treatment2 Interventions
disulfiram and copper gluconate in combination
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Disulfiram
2008
Completed Phase 4
~1300
Copper Gluconate
2008
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Cantex PharmaceuticalsIndustry Sponsor
12 Previous Clinical Trials
364 Total Patients Enrolled
University of UtahLead Sponsor
1,088 Previous Clinical Trials
1,728,347 Total Patients Enrolled
6 Trials studying Multiple Myeloma
274 Patients Enrolled for Multiple Myeloma
Douglas Sborov, MDPrincipal InvestigatorHuntsman Cancer Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies currently available for this clinical trial?

"The data published on clinicaltrials.gov indicates that this medical investigation is recruiting patients now - the trial was first posted in May 2021 and recently updated in March 2022."

Answered by AI

How many participants are currently partaking in this clinical investigation?

"Affirmative, clinicaltrials.gov data shows that this research is currently looking for participants. Since it was first posted on May 21st 2021 and last amended on March 1st 2022, 38 patients are needed to take part in the trial at a single location."

Answered by AI

What potential harms could patients suffer from Disulfiram consumption?

"Our assessment at Power of Disulfiram's safety is rated as a 1, due to the fact that this trial is in Phase One and there are only limited amounts of clinical data highlighting its efficacy."

Answered by AI
~1 spots leftby Mar 2025